Polycystic ovarian syndrome - Pipeline Insight, 2022

DelveInsight’s, “Polycystic ovarian syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Polycystic ovarian syndrome Understanding
Polycystic ovarian syndrome: Overview
Polycystic Ovarian Syndrome (PCOS) is a condition that affects a woman’s hormone levels. Polycystic Ovarian Syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility. Some of the symptoms of PCOS include: Irregular menstrual cycle, too much hair on the face, chin, or parts of the body where men usually have hair, Acne on the face, chest, and upper back, Weight gain or difficulty losing weight, Darkening of skin, particularly along neck creases, in the groin, and underneath breasts. There is no single test to diagnose PCOS. To help diagnose PCOS and rule out other causes of symptoms, medical history and physical exam is evaluated and different tests are performed. There is no cure for PCOS, but the symptoms of PCOS can be managed.

""Polycystic ovarian syndrome - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovarian syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovarian syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovarian syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovarian syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic ovarian syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic ovarian syndrome.

Polycystic ovarian syndrome Emerging Drugs Chapters
This segment of the Polycystic ovarian syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycystic ovarian syndrome Emerging Drugs
• DLBS3233: Dexa Medica
DLBS3233, a new insulin sensitizing agent for Type 2 diabetes, is a combination-bioactive-fraction derived from two herbs, i.e., Lagerstroemia speciosa and Cinnamomum burmannii. Since insulin resistance plays a central pathogenic role in polycystic ovary syndrome (PCOS), DLBS3233 has the potential to benefit women with such a condition, in whom menstrual irregularity, chronic anovulation or infertility are manifested. Dexa Medica completed a phase III clinical trial of DLBS 3233 in women with polycystic ovary syndrome.
Further product details are provided in the report……..

Polycystic ovarian syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Polycystic ovarian syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Polycystic ovarian syndrome
There are approx. 5+ key companies which are developing the therapies for Polycystic ovarian syndrome. The companies which have their Polycystic ovarian syndrome drug candidates in the most advanced stage, i.e. Phase III include, Dexa Medica.
• Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Polycystic ovarian syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic ovarian syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovarian syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovarian syndrome drugs.

Polycystic ovarian syndrome Report Insights
• Polycystic ovarian syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polycystic ovarian syndrome Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Polycystic ovarian syndrome drugs?
• How many Polycystic ovarian syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovarian syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovarian syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polycystic ovarian syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies

• Dexa Medica Group
• AbbVie
• Kindex Pharmaceuticals
• Spruce Biosciences
• Bioresearch
• Forendo Pharma
• Cadila healthcare